Johnson & Johnson
bdpatoday(R)
bdpatoday.com

Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years

The BDPA Legacy

The BDPA Legacy

A D V E R T I S E M E N T

BDPA Chapters: California, Indiana, New Jersey, North Carolina, Massachusetts, and Washington, D.C.

New Brunswick, N.J. – Johnson & Johnson (JNJ), healthcare’s leading, most comprehensive innovation powerhouse, announced manufacturing, research and development, and technology investments of more than $55 billion in the United States over the next four years. This represents a 25% increase in investment compared to the previous four years and builds upon the Company’s already elevated U.S. investment levels resulting from the passage of the 2017 Tax Cuts & Jobs Act.

“Today’s announcements accelerate our nearly 140-year legacy as an American innovation engine tackling the world’s toughest healthcare challenges,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Our increased U.S. investment begins with the ground-breaking of a high-tech facility in North Carolina that will not only add U.S.-based jobs but manufacture cutting edge medicines to treat patients in America and around the world.”

$55 Billion Investment Supports American Innovation & Manufacturing

In addition to the facility in Wilson, North Carolina, the Company’s increased investment in the U.S. over the next four years includes:

  • Three new advanced manufacturing facilities and the expansion of several existing sites across the Company’s Innovative Medicine and MedTech businesses that will create high-paying, high-technology jobs. The Company will share further information on these sites once available.
  • Significant investments in extensive research and development (R&D) infrastructure aimed at developing lifesaving and life-changing treatments in areas such as oncology, neuroscience, immunology, cardiovascular disease, and robotic surgery.
  • Increased technology investments to help make drug discovery and development faster, support workforce training and enhance our business operations.
  • With its increased investment over the next four years, the Company’s U.S. economic impact will build upon its already estimated more than $100 billion per year.
Johnson & Johnson (JnJ) at NSBE2025
NSBE and BDPA Student Members visit Johnson & Johnson’s exhbit at the McCormick Place Convention Cenrter in Chicago, IL during NSBE2025.  — bdpatoday® photo ©2025

Groundbreaking Today in North Carolina Kickstarts U.S. Investment
The North Carolina investment creates jobs starting today in Wilson, North Carolina, where the Company is officially breaking ground on its new, 500,000 square foot, state-of-the-art biologics manufacturing facility.

The North Carolina facility will:

  • Expand our capacity to manufacture next-generation medicines for people living with cancer, immune-mediated and neurological diseases in America and around the world.
  • Support approximately 5,000 jobs during construction and create over 500 positions in North Carolina.
  • Create a $3 billion impact across the state in the first 10 years of operations.

Johnson & Johnson has more manufacturing facilities in the U.S. than in any other country and is a leading investor in American innovation and R&D. With a focus on pharmaceuticals and medical technology, the Company stands alone in its ability to impact the full spectrum of disease. From cardiology to cancer, mental health to vision, cell therapies to robotics, the depth and breadth of Johnson & Johnson’s expertise and capabilities is unique. No company can match Johnson & Johnson’s ability to deliver best-in-class solutions for patients at every step of their journeys.

– Source and top/featured photo: Johnson & Johnson


Johnson & Johnson and BDPA

BDPA Robotics Academy powered by J&J
(Above) BDPA Student Members partricipate in BDPA™ Robotics Academy sessions during #BDPACON24 and Tech & Career expo events last August in Atlanta, GA for the annual robotics challenge and related STEM events. The 2024 Robotics Academy, which was sponsored by Johnson & Johnson, emphasized robotics in the medical and surgical industries. — bdpatoday® photo ©2024

BDPA™ announced several sponsorship renewals for BDPACON last year, including the 2024 Robotics Academy, which was sponsored by Johnson & Johnson and emphasized robotics in the medical and surgical industries. This year’s Robotics Academy is expected to continue and expand its hybrid program across aerospace and defense sectors while introducing more students to new principles of robotics and precision robotics.

Johnson & Johnson and BDPA
Mr. Keyshawn Boughton from McCalister College, representing BDPA Twin Cities, MN (center), was honored with one of the year’s scholarship awards during the annual BDPACON awards gala. He achieved first place in the 2024 Robotics Academy Coding Challenge, which was co-sponsored by Johnson & Johnson and BDPA. Coding challenges for participating students focused on robotics applications within Industry’s HealthTech and MedTech sectors. — BDPA™ photo ©2024

The Association looks forward to enhancing student and instructor engagements in 2025 BDPA™ Robotics Academy sessions, the BDPA™ Student I.T. Education & Scholarship (SITES) Programs, and the Tech & Career Expo events at BDPACON25, scheduled for next August in Atlanta, GA, which is scheduled to feature annual robotics challenges and various STEM events.

Discover more from bdpatoday

Subscribe now to keep reading and get access to the full archive.

Continue reading